Source link : https://www.newshealth.biz/health-news/should-patients-with-cll-take-breaks-from-btk-inhibitors/
HOUSTON — Bruton’s tyrosine kinase inhibitors such as ibrutinib, acalabrutinib, and zanubrutinib have revolutionized the treatment of chronic lymphocytic leukemia (CLL). But should patients take a break from them? At the Society of Hematologic Oncology (SOHO) 2024, two hematologist-oncologists — Inhye Ahn, MD, of Dana-Farber Cancer Institute in Boston, and Kerry A. Rogers, MD, of […]
Author : News Health
Publish date : 2024-09-10 07:44:58
Copyright for syndicated content belongs to the linked Source.
Categories